Filing Details
Aquestive Therapeutics, Inc. (NASDAQ:AQST) filed a Form 8-K with the Securities and Exchange Commission on October 14, 2026, disclosing a material event.
8k filedNASDAQ:AQST
Aquestive Therapeutics, Inc. (AQST) Reports Material Event to SEC
Aquestive Therapeutics, Inc. (NASDAQ:AQST) filed a Form 8-K with the Securities and Exchange Commission on October 14, 2026, disclosing a material event.
At publication ·
What changed
Aquestive Therapeutics, Inc. (NASDAQ:AQST) · 8k filed
- Form
- 8-K
At a glance
Key takeaways
- Aquestive Therapeutics filed a Form 8-K with the SEC on October 14, 2026, disclosing a material event requiring shareholder disclosure.
- The company's stock trades at $4.61 with a market capitalization of $397.2 million.
- Material events reported in 8-K filings may include leadership changes, agreements, acquisitions, asset sales, or guidance changes.
Market Context
Aquestive Therapeutics, Inc.'s stock currently trades at $4.61 with a market capitalization of $397.2M. The Healthcare company's stock moved following the disclosure.
8-K filings report material events that shareholders should know about between regular quarterly or annual reports. These can include leadership changes, material agreements, acquisitions, asset sales, or changes to financial guidance. The specific nature of the event determines its significance for Aquestive Therapeutics, Inc.'s stock.
All SEC filings for Aquestive Therapeutics, Inc. are publicly available through the SEC's EDGAR database. Investors can set up alerts for new filings to stay current on material developments.
Related Tools: View AQST Stock Page
Frequently Asked Questions
Where can I read AQST's SEC filings?
Browse all filings on our AQST SEC filings page.
What types of SEC filings does Aquestive Therapeutics, Inc. file?
Public companies like Aquestive Therapeutics, Inc. file annual reports (10-K), quarterly reports (10-Q), material events (8-K), and insider transactions (Form 4) with the SEC.